News – Page 2 – Sound Bioventures

All Events Fund articles Fund PR Portfolio articles Portfolio PR

VarmX announces appointment of John Glasspool as CEO

2024.11.122024.11.12 / Leadership team fully strengthened to drive next phase of development Leiden, The Netherlands, 12 november 2024 VarmX, a biotech company developing innovative approaches for the bypass of direc ...

The makings of a good venture capitalist in biotech

2024.10.282024.10.28 / Venturing to the great unknown: venture capitalism in biotech. What are some of the key tools in a venture capitalist’s repertoire? By Bibhash Mukhopadhyay at Sound Bioventures Historically ...

ARTHEx biotech

ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1)

2024.10.212024.10.21 / VALENCIA, Spain, Oct. 18, 2024 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expressi ...

Before founding Sound Bioventures, Mr. Breum was a Senior Partner at Lundbeckfonden Ventures, where he worked for 12 years, and led investments and served as a member of the board of directors in companies including Sanifit (sold to Vifor Pharma), Aura Biosciences (Nasdaq: AURA), Spero Therapeutics (Nasdaq: SPRO), Nexstim (Nasdaq First North: NXTM), Biomup (Euronext: BUP).

2024.09.122024.09.12 / Prior to that, he was CEO of the venture-backed diagnostics company, ilochip A/S (technology sold to DELTA, now FORCE Technology). Before that, Mr Breum worked in the pharmaceutical industry for 15 y ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma completes patient recruitment in Phase 2a trial with first-in-class Nck modulator AX-158

2024.08.132024.09.09 / AX-158 has broad potential to treat many autoimmune diseases without causing immunosuppression Psoriasis biomarker panel and PASI scores expected later this year Cambridge, MA, August 13, 2024 ...

Navigating the journey of orphan drug development

2024.06.282024.06.28 / A new drug rarely takes a direct path from idea to patient, especially a first-in-class therapy. For NephroDI Therapeutics, developing a novel approach addressing the critical unmet medical need of a ...

NephroDI Therapeutics Announces Investment by Sound Bioventures to Accelerate Development of NDI-5001 as a Potential First-in-Class Therapy for Pediatric Orphan Kidney Disease

2024.06.202024.09.04 / New funding to take NDI-5001 into and through clinical proof of concept in Congenital Nephrogenic Diabetes Insipidus (NDI) New investment complements previously announced strategic corporate part ...

Johan Kördel Ph.D., Managing Partner - Sound Bioventures

Sound Bioventures: Putting Scandinavian Biotechs on the Global Stage

2024.06.042024.09.09 / In this keynote presentation from the BioStock Global Forum, Sound Bioventures' Managing Partner Johan Kordel discusses the importance of Scandinavian biotch companies taking a strong international p ...

Evolving to the next phase of viral therapy development

2024.05.012024.05.13 / UK-based Theolytics is about to begin the first clinical trials for one of its cancer-fighting viruses. It’s a major step for any biotech company, often reached only after years of adjusting and read ...

Earthquakes, investing in drugs, and how to be decent in Venture Capital.

2024.04.232024.04.24 / Sound Bioventures’ Managing Partner Johan Kördel was recently interviewed by Jonas Söderström from BioStock for the latest episode of their Health and Wealth podcast series. The discussion include ...

Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics

2024.04.172024.05.13 / Sound Bioventures joins strong international syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford New funding enables Theolyt ...

Beyond fundraising: how do venture capitals build early-stage biotechs?

2024.02.292024.02.29 / It’s no secret that venture capital is what drives early-stage drug development in the biotech industry. But beyond being a simple source of cash to spend on research, some VCs play a significant rol ...